Cytisine, also known as baptitoxine, cytisinicline, or sophorine, is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. It has been used medically to help with smoking cessation. Chemically it is classified as a quinolizidine alkaloid and functions pharmacologically as a partial agonist at neuronal nicotinic acetylcholine receptors with preferential affinity for the alpha4beta2 subtype, producing receptor desensitization that reduces craving and withdrawal. As an active pharmaceutical ingredient cytisine is characterized by chromatographic and spectroscopic methods including validated HPLC assays, mass spectrometry and NMR, and is manufactured and formulated as free base or as pharmaceutically acceptable salts depending on product design. The substance is chemically stable under controlled storage but can undergo oxidative N-oxidation and hydrolytic degradation under severe conditions, so specifications and stability-indicating methods are required for product quality control.
Pharmaceutical grade cytisine is typically controlled to tight analytical specifications; a representative quality profile includes assay by validated HPLC at not less than 98.0 percent on an anhydrous basis, water content or loss on drying generally kept at or below 1.5 percent, total chromatographic impurities normally limited to 2.0 percent or less and any single identified related impurity limited to 0.5 percent or lower with unspecified individual impurities commonly specified at 0.1 percent or below. Heavy metals are typically specified at 20 parts per million or less and residual solvents are controlled to ICH Q3C limits for the solvent class present for example methanol at or below 3000 ppm where applicable. Related compounds monitored in both API and botanical material include other quinolizidine alkaloids such as sparteine, lupanine and anagyrine plus cytisine N-oxide and common oxidative or ring-modified degradation products; permitted amounts for these related alkaloids in the API are typically in the low tenths of a percent range depending on toxicological qualification and regulatory requirements.
Cytisine is used as a pharmacological aid to support smoking cessation, acting at nicotinic receptors to reduce withdrawal symptoms and craving; it is supplied as an active pharmaceutical ingredient for formulation into oral dosage forms and has been evaluated in randomized clinical trials for this indication.
Cytisine occurs naturally in several members of the Fabaceae family, most notably species of the genera Laburnum, Cytisus and Sophora; it accumulates as one of a group of quinolizidine alkaloids in seeds and other plant tissues, and levels vary by species, plant part and growing conditions.
Clinical evidence from randomized controlled trials and systematic reviews indicates cytisine increases smoking cessation rates compared with placebo and has demonstrated efficacy comparable to some licensed smoking cessation medicines in certain studies; benefit must be balanced with safety and tolerability data and use should follow local regulatory guidance and clinical practice.
